Wilkinson Walsh + Eskovitz co-founder Alexandra Walsh is our Litigator of the Week, persuading a Philadelphia jury to find for the defense in a bellwether trial over the adequacy of the warning labels for the blood thinner Xarelto.

According to The Legal Intelligencer, more than 1,900 Xarelto cases are pending in the mass tort program in the Philadelphia Court of Common Pleas. (Another 18,000 cases are pending in a federal MDL.) The blood thinner, which is made by Bayer and Johnson & Johnson, is a lucrative target–it generated $5.39 billion in sales in 2016.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]